Date | Time | Source | Announcement |
---|---|---|---|
15 Oct 2009 | 09:52 AM | Holding(s) in Company | |
12 Oct 2009 | 05:02 PM | Issue of Equity | |
12 Oct 2009 | 07:00 AM | Issue of Equity | |
09 Oct 2009 | 04:11 PM | Holding(s) in Company | |
08 Oct 2009 | 07:00 AM | Holding(s) in Company | |
06 Oct 2009 | 07:00 AM | Cancer Research Programme to | |
30 Sep 2009 | 07:00 AM | Total Voting Rights | |
21 Sep 2009 | 07:00 AM | Holding(s) in Company | |
16 Sep 2009 | 04:15 PM | Holding(s) in Company | |
10 Sep 2009 | 07:00 AM | Holding(s) in Company | |
08 Sep 2009 | 07:00 AM | Issue of Equity | |
03 Sep 2009 | 10:57 AM | Holding(s) in Company | |
28 Aug 2009 | 12:57 PM | Statement re Share Price Move | |
05 Jun 2009 | 10:53 AM | Statement re. Bulletin Board | |
24 Apr 2009 | 11:03 AM | Holding(s) in Company | |
20 Apr 2009 | 01:22 PM | Holding(s) in Company | |
23 Mar 2009 | 03:08 PM | Holding(s) in Company | |
23 Mar 2009 | 12:56 PM | Statement re share price move | |
23 Feb 2009 | 07:00 AM | Half Yearly Report | |
13 Feb 2009 | 04:23 PM | Holding(s) in Company | |
27 Jan 2009 | 10:46 AM | Result of AGM | |
13 Jan 2009 | 12:30 PM | Change of Registered Office | |
22 Dec 2008 | 02:47 PM | Publication of Report & Accou | |
22 Dec 2008 | 07:29 AM | Restoration of Listing | |
27 Nov 2008 | 02:44 PM | Final Results | |
16 Sep 2008 | 11:45 AM | End of Offer Period | |
29 Aug 2008 | 01:56 PM | Directorate Change and Update | |
26 Aug 2008 | 07:00 AM | Disposal | |
11 Jul 2008 | 05:59 PM | Directorate Change | |
09 Jul 2008 | 03:45 PM | Statement re. Suspension | |
01 Jul 2008 | 04:39 PM | Directorate Change | |
26 Jun 2008 | 12:27 PM | Change of Broker | |
25 Jun 2008 | 07:00 AM | Three Repeat Business Agreeme | |
19 Jun 2008 | 07:00 AM | Corporate update | |
14 May 2008 | 07:00 AM | Restructuring | |
02 May 2008 | 07:01 AM | Strategic Review | |
24 Apr 2008 | 11:07 AM | Notification of Shareholder | |
14 Apr 2008 | 09:26 AM | Fundraising | |
10 Apr 2008 | 07:01 AM | Presentation at AACR | |
31 Mar 2008 | 07:00 AM | Extension of Collaboration | |
06 Mar 2008 | 07:01 AM | Research Update | |
06 Mar 2008 | 07:00 AM | Interim Results | |
04 Feb 2008 | 07:00 AM | Notice of Results | |
12 Dec 2007 | 07:01 AM | Genentech Agreement | |
30 Nov 2007 | 07:00 AM | Total Voting Rights | |
19 Nov 2007 | 07:00 AM | Director/PDMR Shareholding | |
16 Nov 2007 | 07:01 AM | Board Appointment | |
15 Nov 2007 | 03:07 PM | Placing of Shares | |
15 Nov 2007 | 12:59 PM | AGM Statement | |
31 Oct 2007 | 03:58 PM | Total Voting Rights |
Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.
The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.
SAR share price listed on AIM in 2004 under the ticker SAR.